NRC Health Q4 TRCV rises 8% to USD 144.1 million

Reuters
02/03
NRC Health Q4 TRCV rises 8% to USD 144.1 million

NRC Health $(NRC)$ reported its financial results for the fourth quarter (Q4) and full year (FY) 2025. For Q4 2025, revenue was USD 35.19 million. Net income for the quarter was USD 1.80 million, with basic and diluted earnings per share $(EPS)$ both at USD 0.08. For the full year 2025, revenue totaled USD 137.39 million. Net income for the year was USD 11.60 million, with basic EPS at USD 0.50 and diluted EPS at USD 0.50. Total recurring contract value (TRCV) in Q4 2025 increased 8 percent year-over-year to USD 144.10 million. Cash flow from operations for the quarter rose 13 percent year-over-year to USD 7.20 million. CEO Trent Green commented on the quarter, highlighting the company's strong execution and the foundation established for continued progress. Green noted that momentum is building across NRC Health’s portfolio and emphasized the importance of the company’s mission in supporting healthcare leaders as they navigate industry complexities.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NRC - National Research Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20260203161940) on February 03, 2026, and is solely responsible for the information contained therein.

應版權方要求,你需要登入查看該內容

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10